Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | RAD51C |
| Variant | R193* |
| Impact List | nonsense |
| Protein Effect | loss of function |
| Gene Variant Descriptions | RAD51C R193* results in a premature truncation of the Rad51c protein at amino acid 193 of 376 (UniProt.org). R193* confers a loss of function to Rad51c as demonstrated by decreased Rad51 foci in response to DNA damage and decreased homologous recombination repair in cultured cells and reduced interaction with Xrcc3 and Rad51b in yeast assays (PMID: 28588062). |
| Associated Drug Resistance | |
| Category Variants Paths |
RAD51C mutant RAD51C inact mut RAD51C R193* |
| Transcript | NM_058216.3 |
| gDNA | chr17:g.58703201C>T |
| cDNA | c.577C>T |
| Protein | p.R193* |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| XM_006722001 | chr17:g.58703201C>T | c.577C>T | p.R193* | RefSeq | GRCh38/hg38 |
| NM_058216.3 | chr17:g.58703201C>T | c.577C>T | p.R193* | RefSeq | GRCh38/hg38 |
| XM_006722001.5 | chr17:g.58703201C>T | c.577C>T | p.R193* | RefSeq | GRCh38/hg38 |
| XM_047436505.1 | chr17:g.58703201C>T | c.577C>T | p.R193* | RefSeq | GRCh38/hg38 |
| XM_006722002 | chr17:g.58703201C>T | c.577C>T | p.R193* | RefSeq | GRCh38/hg38 |
| XM_006722002.5 | chr17:g.58703201C>T | c.577C>T | p.R193* | RefSeq | GRCh38/hg38 |
| NM_058216 | chr17:g.58703201C>T | c.577C>T | p.R193* | RefSeq | GRCh38/hg38 |
| XM_006722001.4 | chr17:g.58703201C>T | c.577C>T | p.R193* | RefSeq | GRCh38/hg38 |
| NM_058216.2 | chr17:g.58703201C>T | c.577C>T | p.R193* | RefSeq | GRCh38/hg38 |
| XM_006722002.4 | chr17:g.58703201C>T | c.577C>T | p.R193* | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| RAD51C R193* | ovarian carcinoma | predicted - sensitive | Rucaparib | Case Reports/Case Series | Actionable | In a clinical case study, an ovarian carcinoma patient harboring a RAD51C R193* germline mutation demonstrated a partial response when treated with Rubraca (rucaparib) (PMID: 28588062). | 28588062 |
| RAD51C R193* | ovarian cancer | sensitive | Niraparib + TNG348 | Preclinical - Pdx | Actionable | In a preclinical study, treatment with the combination of TNG348 and Zejula (niraparib) resulted in greater inhibition of tumor growth than either agent alone in a patient-derived xenograft (PDX) model of ovarian cancer harboring RAD51C R193* (PMID: 39886906). | 39886906 |